AIM-NASH: FDA Qualifies First AI Tool to Assess Severe Fatty Liver Disease in Drug Trials

The U.S. Food and Drug Administration (FDA) has approved the first-ever artificial intelligence tool designed to assist doctors in evaluating severe fatty liver disease during clinical drug trials.

• The tool is now publicly available for use in any drug development program within its qualified context of use.

What AIM-NASH Does

• AIM-NASH, a cloud-based system, analyzes liver tissue images to detect:
  • Fat accumulation
  • Inflammation
  • Fibrosis (scarring)
• It generates scores aligned with a standard liver disease scoring system, which are then reviewed by doctors.

Advancing MASH Drug Development

• The tool is expected to streamline clinical trials for Metabolic-dysfunction Associated Steatohepatitis (MASH).
• MASH affects millions of Americans and can progress to liver failure or liver cancer.
• Traditional assessment requires multiple pathologists to independently review biopsies, a process that is slow, labor-intensive, and sometimes inconsistent.

Benefits of the AI Tool

• Provides standardized, reproducible assessments.
• Reduces time, cost, and variability in reading liver biopsy slides during trials.
• May accelerate the arrival of new MASH treatments by improving efficiency in the research pipeline.

Human Oversight Retained

• AIM-NASH does not replace medical experts.
• Doctors still perform the final interpretation of AI-generated results.

Source: USFDA